Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (Nasdaq: ARQT) launched a new virtual health platform to expand access to care and its ZORYVE (roflumilast) portfolio for chronic inflammatory skin diseases.
The platform connects eligible individuals with independent, board-certified dermatologists for digital evaluation, diagnosis, and, when appropriate, treatment, complementing traditional in-office dermatology care.
Arcutis (Nasdaq:ARQT) received FDA approval to expand ZORYVE (roflumilast) cream 0.3% for plaque psoriasis to children as young as age 2, including intertriginous areas. ZORYVE is a once-daily, non-steroidal topical for use anywhere on the body, with no duration limits.
The decision is based on a 4-week MUSE study and a 24-week extension in children 2–5, which showed safety and efficacy consistent with prior adolescent and adult trials. This is the seventh FDA approval for ZORYVE in four years. Arcutis highlights broad availability and access programs, including ZORYVE Direct savings and Arcutis Cares assistance.
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 44,000 restricted stock units to six newly hired employees under its 2022 Inducement Plan, effective June 1, 2026.
The RSUs vest over four years, with 25% vesting on each annual anniversary, consistent with Nasdaq Listing Rule 5635(c)(4).
Arcutis (Nasdaq: ARQT)/b) announced publication of new expert consensus guidance on in the American Journal of Clinical Dermatology. Developed by the Arcutis-supported Genital Psoriasis Wellness Consortium, the paper provides age-specific recommendations for pediatric, adult, and older patients, emphasizing routine genital assessment, empathetic communication, and individualized treatment. Genital involvement affects about two-thirds of the nine million people with plaque psoriasis in the United States. The guidance advises minimizing long-term topical corticosteroid use and considering non-steroidal options where appropriate.
Arcutis (Nasdaq: ARQT) announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, held June 8–10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 p.m. ET, with a webcast and 180-day replay on the company website.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported inducement equity grants to 40 newly hired employees under its 2022 Inducement Plan, with a grant date of May 1, 2026.
The company granted 269,000 restricted stock units and options to purchase 70,000 shares. RSUs vest 25% annually over four years. Options vest 25% after one year and monthly over the next three years, have a 10-year term, and an exercise price of $23.35 per share.
Arcutis (Nasdaq: ARQT) reported Q1 2026 results: ZORYVE net product revenue $105.4M (65% YoY, -17% vs Q4 2025). The company generated $2.2M positive operating cash flow, submitted an sNDA for ZORYVE cream 0.05% in infants 3–24 months, and initiated Phase 1 for ARQ-234.
Q1 R&D rose to $30.6M largely due to a $10M Ducentis milestone; net loss was $11.3M. Full-year 2026 revenue guidance: $480M–$495M.
Arcutis (Nasdaq: ARQT) submitted an sNDA to the FDA to expand ZORYVE cream 0.05% (roflumilast) for treatment of mild-to-moderate atopic dermatitis in infants aged ≥3 months to 24 months.The filing is supported by a Phase 1 PK trial (n=19) and the Phase 2 INTEGUMENT-INFANT study (n=101) reporting tolerability and multiple efficacy endpoints, including 34.4% vIGA-AD success at Week 4 and 58.3% EASI-75 at Week 4.
Arcutis (Nasdaq: ARQT) announced that ZORYVE® (roflumilast) cream received a strong recommendation with high certainty in the American Academy of Dermatology pediatric atopic dermatitis guidelines (Apr 22, 2026).
The guidelines recommend ZORYVE 0.05% for ages 2–5 and ZORYVE 0.15% for ages 6 and older, citing clinically meaningful improvements in disease severity and itch and low treatment discontinuation rates.
Arcutis (Nasdaq: ARQT) will report first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 PM ET.
A live webcast and presentation materials will be available in the Events section of the company website, with a replay posted on Arcutis investor site after the call.